case_images: PMC7569175_01
case_images: Next-generation sequencing identified an EGFR compound mutation consisting of L858R in exon 21 (A) and D761Y in exon19 (B) from plasma.
case_images: OTT-13-10447-g0001.jpg
case_images: PMC7569175_01_OTT-13-10447-g0001.jpg
case_images: f0001
case_images: Only two mutations were found, namely EGFR-L858R in exon 21 and D761Y in exon 19 (allelic frequency, AF: 4.34%, Figure 1).
case_images: Diagram of the course of disease management, showing different treatment regimens prescribed and the results of mutation analyses.
case_images: OTT-13-10447-g0002.jpg
case_images: PMC7569175_01_OTT-13-10447-g0002.jpg
case_images: f0002
case_images: The PFS of icotinib was therefore 8.2 months (Figures 2 and 3). The best response of osimertinib treatment was SD and the PFS was 19 months (Figures 2 and 3). On the latest follow-up in April, 2020, neither of the primary and metastatic lesions presented notable change in size (Figures 2 and 3).
case_images: Representative CT images at indicated time points, shown along with corresponding treatment regimen and efficacy evaluation.
case_images: OTT-13-10447-g0003.jpg
case_images: PMC7569175_01_OTT-13-10447-g0003.jpg
case_images: f0003
case_images: The PFS of icotinib was therefore 8.2 months (Figures 2 and 3). The best response of osimertinib treatment was SD and the PFS was 19 months (Figures 2 and 3). On the latest follow-up in April, 2020, neither of the primary and metastatic lesions presented notable change in size (Figures 2 and 3).